Back to search

Peptide record

TPDB12942

Oligo10 Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB12942
Oligo10
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb dbAMP PD_Hemolysis DBAASP
standard
No
A 15-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
FAKALKALLKALKAL
Physicochemical Analysis
C78H139N19O16
RNDCEQGHIMPSTWYV
AL
1599.08
11.00
4
0
11
+4
-0.82
1.013
163.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
5
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
4
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 4 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
15
C78H139N19O16
1599.08
11.00
+4
-0.82
1.013
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
16.0 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/m
Evidence 2 Activity

Activity

MIC
Antibacterial
63.0 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), a
Evidence 3 Activity

Activity

MIC
Antibacterial
63.0 µg/mL

Target

K. pneumonia

Source & Reference

dbAMP

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 4 Activity

Activity

MIC
Antibacterial
16.0 µg/mL

Target

E. faecium

Source & Reference

dbAMP

Other

E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 5 Activity

Activity

MIC
Antibacterial
4.0 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP

Other

aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 6 Activity

Activity

MIC
Antibacterial
2.0 µg/mL

Target

C. acnes

Source & Reference

dbAMP

Other

. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 7 Activity

Activity

MIC
Antifungal
16.0 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/m
Evidence 8 Activity

Activity

MIC
Antifungal
63.0 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), a
Evidence 9 Activity

Activity

MIC
Antifungal
63.0 µg/mL

Target

K. pneumonia

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 10 Activity

Activity

MIC
Antifungal
16.0 µg/mL

Target

E. faecium

Source & Reference

dbAMP CAFPdb Antifungipept

Other

E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 11 Activity

Activity

MIC
Antifungal
4.0 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP CAFPdb Antifungipept

Other

aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 12 Activity

Activity

MIC
Antifungal
2.0 µg/mL

Target

C. acnes

Source & Reference

dbAMP CAFPdb Antifungipept

Other

. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 13 Activity

Activity

LD50
Toxicity
37 µg/mL
Cytotoxic
LD50 | 37 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 14 Activity

Activity

50% Hemolysis
Toxicity
6 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 6 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 15 Activity

Activity

IC50
Toxicity
218.21 µg/mL
Cytotoxic
IC50 | 218.21 | µg/mL | target cell: Mouse fibroblasts BALB/3T3

Target

Mouse fibroblasts BALB/3T3

Source & Reference

NA
DBAASP
Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections. | J Antibiot (Tokyo) | 2023
Evidence 16 Activity

Activity

IC50
Toxicity
241.54 µg/mL
Cytotoxic
IC50 | 241.54 | µg/mL | target cell: Human dermal fibroblasts

Target

Human dermal fibroblasts

Source & Reference

NA
DBAASP
Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections. | J Antibiot (Tokyo) | 2023
Evidence 17 Activity

Activity

18% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
18% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections. | J Antibiot (Tokyo) | 2023
Evidence 18 Activity

Target

Cutibacterium acnes

Source & Reference

DBAASP
Evidence 19 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis